Buy or sell Synergy Pharmaceuticals stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Synergy Pharmaceuticals Stock

Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions.

Founded

1992

Headquarters

New York NY, US

Total Funding

$407M

About Synergy Pharmaceuticals Stock

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Funding History

February 2009$15.9M
August 2010$400K
June 2011$1.2M
May 2016$89.8M
September 2017$300M

Management

President & CEO

Gary S. Jacob

CMO

Patrick H. Griffin

CSO

Kunwar Shailubhai

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Synergy Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo